Updated: 07 Jan 2001
The Lysosomal Acid Lipase (LAL) Deficiency Knowledge Centre contains a range of accurate, informative clinical content for healthcare professionals. The disease awareness section presents epidemiology, pathophysiology and diagnosis information, among others. The treatment section details the drug characteristics, safety and efficacy of sebelipase alfa – the first and only licenced treatment for LAL deficiency. The resources section contains further clinical content including a video channel presenting expert opinions on diagnostic approach and current prognosis.
Developed by EPG Health Media (Europe) Ltd for epgonline.org, in collaboration and with content provided by Alexion Pharma GmbH
The Oral Anticoagualtion Reversal Knowledge Centre is intended to provide healthcare professionals with accurate information on the approaches to oral anticoagulation reversal for patients who experience or are at risk of significant bleeding, or require surgery. Content is arranged within illustrated and referenced sections including management of bleeding risk, oral anticoagulants, symposium highlights, key publication summaries and more.
This resource is developed by EPG Health Media (Europe) Ltd for epgonline.org in collaboration with CSL Behring, with content provided by CSL Behring.
This resource is not intended for healthcare professionals outside Europe.
See disease awareness facts and stats, information on sebelipase alfa (the first and only licensed treatment for LAL-D) and resources section, including expert video channel…